0
Articles |

Intravenous Thrombolysis in Acute Myocardial Infarction

E. Magnus Ohman, MD, FCCP; Robert A. Harrington, MD; Christopher P. Cannon, MD; Giancarlo Agnelli, MD; John A. Cairns, MD; J.Ward Kennedy, MD
Author and Funding Information

Correspondence to: E. Magnus Ohman, MD, FCCP, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715; e-mail: ohman001@mc.duke.edu



Chest. 2001;119(1_suppl):253S-277S. doi:10.1378/chest.119.1_suppl.253S
Text Size: A A A
Published online

Extract

Fibrinolytic therapy for acute myocardial infarction (MI) has been one of the most potent treatments ever developed for a condition that kills more patients worldwide than any other. This review will focus on approved agents and the randomized trials that have led to their widespread use. The use of adjunctive antithrombotic therapies, such as aspirin and heparin, also will be discussed, but a more complete discussion of these therapies is located in other sections of this supplement. A brief overview of new adjunctive therapies, such as platelet glycoprotein (GP) IIb/IIIa inhibitors and direct thrombin inhibitors, will be provided. This section also will explore how therapeutic success can be evaluated, cost-effectiveness analysis, and complications with this therapy. Finally, we will provide a set of recommendations for the use of fibrinolytic therapy in acute MI based on the published literature.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
Acute ST-Segment Elevation Myocardial Infarction*: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543